An observational study in Metastatic Castration-resistant Prostate Cancer, sponsored by Janssen-Cilag Farmaceutica Ltda.. Completed at 1 site in Brazil. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-03.
Sponsored by Janssen-Cilag Farmaceutica Ltda. (part of Johnson & Johnson) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 88 studies in Prostatic Neoplasms by Johnson & Johnson — 9 open to participants now, 23 under way, 9 of them phase 3. Prostatic Neoplasms · Johnson & Johnson.
Among the 88 studies in Prostatic Neoplasms by Johnson & Johnson, this one is the 13th largest by enrollment of the 16 observational ones that give a count, is one of 7 that started in 2020, is one of 16 observational ones, and was the 64th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →9 of the 88 studies in Prostatic Neoplasms by Johnson & Johnson are open now, in 8 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States, Israel
Ages 18+ · Men only
Janssen Research & Development, LLC · Sites in United States, Australia, China and 1 more country
Ages 18+ · Men only
Janssen Research & Development, LLC · Sites in United States, Israel
Ages 18+ · Men only
Janssen Research & Development, LLC · Sites in United States, United Kingdom
Ages 18+
Janssen Cilag S.A.S. · Sites in France
Ages 18+ · Men only
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
88 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 24 · Phase 3 15 · Phase 4 2
First in 1995; this study’s year is marked. 7 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is below the median of 200 across 1,312 observational studies indexed under Prostatic Neoplasms.
Median enrollment 82 across the 68 interventional studies, 300 across the 16 observational. Of the 58 that completed or were terminated, 24 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen-Cilag Farmaceutica Ltda., one of the names counted as Johnson & Johnson. Under that name alone:
Janssen-Cilag Farmaceutica Ltda. is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
9 of the studies in Prostatic Neoplasms by Johnson & Johnson that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03767244Phase 3Janssen Research & Development, LLCA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | 2026-12-01 |
| NCT02531516Phase 3Aragon Pharmaceuticals, Inc.An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS | 2027-03-01 |
| NCT04644770Janssen Research & Development, LLCA Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer | 2026-12-08 |
| NCT04662580Janssen Research & Development, LLCARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer | 2026-12-31 |
| NCT07319871Janssen Research & Development, LLCA Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer | 2027-01-07 |
Add all 9 to your calendar (.ics) → With an account.
Among the 88 studies in Prostatic Neoplasms by Johnson & Johnson, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to evaluate the influence of HSD3B1 (1245C) germline variant and potential pharmacodynamic markers on abiraterone activity in participants with metastatic castration-resistant prostate cancer after unresponsive use of diethylstilbestrol.
The population of this study comprised of participants with metastatic castration-resistant prostate cancer with disease progression following the use of diethylstilbestrol (DES) who participated in the Abira-DES study (NCT02217566) in which they were treated with abiraterone acetate.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with metastatic castration resistant prostate cancer (mCRPC) will be evaluated for genetic polymorphism and pharmacodynamic parameters from serum and plasma samples collected during the Abira-DES study (NCT02217566). Serum and plasma samples were collected after use of diethylstilbestrol (DES) and subsequent abiraterone acetate therapy. Peripheral blood samples were collected prior to initiation of abiraterone acetate therapy, after 12 weeks of therapy, and at the time of disease progression (evaluated by prostate specific antigen \[PSA\] response).
Other: Serum and plasma samples analysis
This is a non-interventional study and no drug will be given as part of this study. Serum and plasma samples will be collected from the participants with metastatic castration-resistant prostate cancer to evaluate genetic polymorphism and pharmacodynamic parameters.
Percentage of Participants with and Without HSD3B1 (1245C) Germline Variant'
Percentage of participants with and without HSD3B1 (1245C) germline variant will be determined to evaluate the influence of HSD3B1 (1245C) germline variant on the response to abiraterone as a predictive fact.
Time frame: Up to 12 months
Levels of HSD3B1 (1245C) Germ Variant
Levels of HSD3B1 (1245C) germline variant will be determined to evaluate the response to abiraterone acetate as a predictive factor.
Time frame: Up to 12 months
Levels of Metabolite Delta-(4)-Abiraterone (D4A) During the Abiraterone Acetate During Treatment Phase
Levels of metabolite D4A during the abiraterone acetate during treatment phase will be evaluated.
Time frame: 12 Weeks
Testosterone Levels in Participants Treated with Abiraterone Acetate
Testosterone levels of participants treated with abiraterone acetate will be evaluated by the molecular analyses.
Time frame: Up to 12 months
SDHEA Levels in Participants Treated with Abiraterone Acetate
SDHEA levels of participants treated with abiraterone acetate will be evaluated by the molecular analyses.
Time frame: Up to 12 months
Correlation Between HSD3B1 (1245C) Variant and Testosterone Levels
Correlation between HSD3B1 (1245C) variant and testosterone levels will be reported. The genotyping of the HSD3B1 (1245 A\> C) germline variant will be performed by Sanger sequencing.
Time frame: Up to 12 months
Correlation Between HSD3B1 (1245C) Variant and SDHEA Levels
Correlation between HSD3B1 (1245C) variant and SDHEA levels will be reported. The genotyping of the HSD3B1 (1245 A\> C) germline variant will be performed by Sanger sequencing.
Time frame: Up to 12 months
Correlation Between HSD3B1 (1245C) Variant and Clinical Response
Correlation between HSD3B1 (1245C) variant and clinical response will be performed by univariate and multivariate analyses.
Time frame: Up to 12 months
Correlation Between D4A Levels with Testosterone Dosage
Testosterone ultrasensitive dosages will be performed on participant serum samples. Testosterone dosage will be performed by liquid chromatography coupled with tandem mass spectrometry.
Time frame: Up to 12 months
Correlation Between D4A Levels with SDHEA Dosage
SDHEA ultrasensitive dosages will be performed on participant serum samples. Dosage will be performed by liquid chromatography coupled with tandem mass spectrometry.
Time frame: Up to 12 months
Correlation Between D4A Levels with Clinical Response
Correlation between D4A levels with clinical response will be performed by univariate and multivariate analyses.
Time frame: Up to 12 months
Ran from Mar 2020 to primary completion in Nov 2020, 7 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Janssen-Cilag Farmaceutica Ltda. →